



## VivaGel® condom receives regulatory approval in Europe

**Melbourne, Australia; 20 November 2019:** Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has been granted marketing approval for the VivaGel® condom in Europe.

The VivaGel® condom is a world-first product based on innovative Australian technology. It is the only condom of its type incorporating the proprietary compound, astodrimer sodium (SPL7013, VivaGel®) in the condom lubricant. The VivaGel® condom is also approved for sale in Japan, Canada and Australia. The European approval applies to all 28 member states of the European Union, including the United Kingdom, as well as the four member countries of the European Free Trade Association with a total population of approximately 525 million people.

Starpharma's marketing partner in Europe, LifeStyles (formerly Ansell) will now undertake marketing preparations ahead of the launch of the VivaGel® condom under the brand name Absolute™ DUAL PROTECTION. LifeStyles is the world's No. 1 sexual wellness company with prime latex brands such as LifeStyles®, Jissbon®, Manix®, Unimil®, Blowtex®, Mates®, Akuel® and others, as well as the fast-growing, highly innovative non-latex condom brand SKYN®.

Starpharma Chief Executive Officer, Dr Jackie Fairley, said, "It's great to have another important market approved for the VivaGel® condom and to achieve a further commercial milestone for our VivaGel® portfolio. The global condom market was valued at US\$7.9B in 2018<sup>1</sup> and projected to grow by 8.5% per year<sup>1</sup>. Europe is a major region and our partner LifeStyles is a significant player in that market."

Jeyan Heper, LifeStyles' CEO, said "LifeStyles is a global leader in sexual wellness. We are committed to making safe sex fun by offering new and unique products, and we're delighted to add the highly innovative VivaGel® condom to the range we offer in Europe. The Absolute™ DUAL PROTECTION condom is a great example of a new and ground-breaking sexual-health product."

### **About the VivaGel® condom**

*The VivaGel® condom is a world-first product based on innovative Australian technology. It is the only condom of its type, providing barrier protection and incorporating the proprietary compound, astodrimer sodium (SPL7013, VivaGel®) in the condom lubricant. VivaGel® has been proven in laboratory studies to inactivate up to 99.9% of HIV, HSV and HPV.*

---

### About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.

---

<sup>1</sup> Condom Market Size, Share & Trends Analysis Report By Material Type (Latex, Non-Latex), By Product (Male Condoms, Female Condoms), By Distribution Channel (Mass Merchandizers, Drug Stores, E-Commerce), And Segment Forecasts, 2019 - 2026  
<https://www.grandviewresearch.com/industry-analysis/condom-market>



**VivaGel®:** Starpharma's women's health product - VivaGel® BV is based on SPL7013, astodimer sodium, a proprietary dendrimer. VivaGel® BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe) and Fleurstat BVgel (Australia) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Japan under Okamoto's 003 brand, and in Australia and Canada under the LifeStyles Dual Protect® brand.

**DEP® - Dendrimer Enhanced Product®:** Starpharma's DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has two internal DEP® products – DEP® docetaxel and DEP® cabazitaxel - in clinical development in patients with solid tumours, with DEP® irinotecan due to commence clinical trials shortly. Starpharma's partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca's major marketed oncology medicines.

[Starpharma.com](http://Starpharma.com) | [Twitter](#) | [LinkedIn](#)

#### Media

##### WE Buchan Consulting

Rebecca Wilson  
Mob: +61 417 382 391  
[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Arthur Chan  
+61 2 9237 2805  
[achan@buchanwe.com.au](mailto:achan@buchanwe.com.au)

#### Starpharma

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)

#### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

#### Trademarks notice

VivaGel® and DEP® are trademarks of Starpharma.

LifeStyles, Jissbon, Manix, Unimil, Blowtex, Mates, Akuel, Skyn and related brand marks are trademarks of LifeStyles Healthcare Pte. Ltd. in various jurisdictions.